New treatment for cannabis use disorder
Treatment for cannabis use disorder
This study is working on a new pill to help people who have trouble with cannabis use, aiming to reduce cravings and make it easier to manage without serious side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artiam Bio INC. NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project ID | NIH-10546566 on NIH RePORTER |
What this research studies
This research aims to develop a new medication for cannabis use disorder (CUD), which affects millions of Americans. The approach involves creating a second-generation partial inverse agonist of the cannabinoid 1 receptor (CB1), designed to reduce cravings and the rewarding effects of cannabis without causing significant adverse effects. The medication is expected to be taken orally and is being developed to have a better safety profile compared to previous treatments. This innovative pharmacotherapy could provide a much-needed solution for individuals struggling with CUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cannabis use disorder who are seeking treatment options.
Not a fit: Patients who do not have cannabis use disorder or those who are not interested in pharmacotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective medication that helps individuals overcome cannabis use disorder.
How similar studies have performed: Previous research has shown that targeting the cannabinoid receptors can be effective in treating substance use disorders, indicating a promising avenue for this new approach.
Where this research is happening
Cary, United States
- Artiam Bio INC. — Cary, United States (Active)
Researchers
- Principal investigator: Seltzman, Herbert H — Artiam Bio INC.
- Study coordinator: Seltzman, Herbert H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.